Sign in
Taking peoplePhase 2

Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma: a Phase 2 Study.

Key facts

Who runs it
Kidney Cancer Research Bureau
Where
Russia8 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
40 people, planned
Started
15 Aug 2025
Expected to end
30 Dec 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Lenvatinib
  • Pembolizumab
  • everolimus
Record updated
16 November 2026

Who can take part

Age
18 months and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Histologically confirmed chromophobe renal cell carcinoma
  • Measurable disease according to RECIST version 1.1
  • ECOG performance status of 0-3
  • Cohort A: No prior systemic therapy for metastatic disease
  • Cohort B: Disease progression following prior systemic therapy and no previous exposure to lenvatinib
  • Adequate bone marrow, hepatic, and renal function
  • Signed informed consent

Who cannot take part

  • Major surgery without adequate postoperative recovery or a serious non-healing wound
  • Uncontrolled or symptomatic central nervous system metastases or leptomeningeal disease
  • Uncontrolled hypertension despite appropriate antihypertensive treatment
  • Clinically significant uncontrolled cardiovascular disease
  • Active infection requiring systemic treatment
  • Active clinically significant bleeding or a high risk of severe hemorrhage
  • Gastrointestinal conditions that significantly impair the absorption of oral study medications
  • Known severe hypersensitivity to any component of the assigned study treatment
  • Current pneumonitis or interstitial lung disease
  • Any medical or psychiatric condition that, in the investigator's judgment, compromises patient safety or adherence to study procedures
  • Cohort A only: Active autoimmune disease requiring systemic immunosuppressive treatment, or a requirement for chronic systemic immunosuppression, excluding physiological corticosteroid replacement
  • Pregnancy or breastfeeding

This trial is currently available in Russia.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Chromophobe renal cell carcinoma (chRCC) accounts for approximately 5% of RCC cases and has distinct morphological and molecular features. However, advanced chRCC follows an aggressive clinical course and responds poorly to standard regimens developed for clear cell RCC.

Read full original descriptionShow less

Lenvatinib plus everolimus (LEN+EVE) has demonstrated clinical activity in clear cell RCC (Study 205), with responses also reported in non-clear cell subtypes, including chRCC. Lenvatinib plus pembrolizumab (LEN+PEMBRO) demonstrated a high objective response rate (ORR) in KEYNOTE-B61, including in the chRCC subgroup.

These findings support conducting a prospective phase 2 study specifically dedicated to this rare subtype to provide direct evidence of the efficacy and safety of these two active combinations.

The 2 groups in the trial

  • Cohort A: first-line lenvatinib plus pembrolizumabTreatment being tested

    lenvatinib 20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks

    Treatment: Lenvatinib and Pembolizumab

  • Cohort B: later-line lenvatinib plus everolimusTreatment being tested

    lenvatinib 18 mg orally once daily in combination with everolimus 5 mg orally once daily

    Treatment: Lenvatinib and everolimus

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-label, Multicenter, Phase 2 Study of First-line Lenvatinib Plus Pembrolizumab and Later-line Lenvatinib Plus Everolimus in Patients With Metastatic Chromophobe Renal Cell Carcinoma.
Record updated
16 November 2026